Sharma Umesh, Yadav Birendra Kumar, Rai Ujwal, Pradhan Akash, Lama Jyoti Bhaju, Thakur Alok
Purbanchal Cancer Hospital, Birtamode -05, Jhapa, Nepal.
B&C Medical College and Teaching Hospital, Birtamode -05, Jhapa, Nepal.
BMC Cancer. 2025 Jul 1;25(1):1098. doi: 10.1186/s12885-025-14475-4.
Cervical cancer is a major public health challenge in Nepal, with delayed diagnosis due to limited screening and infrastructure. Accurate staging, critical for treatment planning, integrates MRI with clinical examination (CE) per 2018 FIGO guidelines. This study evaluates MRI-CE concordance in staging cervical cancer at a Nepalese tertiary center, hypothesizing moderate agreement with MRI detecting occult spread missed by CE.
This retrospective study (2020-2023) included 76 patients with histologically confirmed cervical cancer and complete MRI (1.5T, T2/DWI/post-contrast) and CE (pelvic exam, punch/cone biopsy) data at Purbanchal Cancer Hospital. Staging followed FIGO 2018 guidelines. Univariate analyses summarized patient profiles; MRI sensitivity, PPV, and Cohen's κ assessed concordance. Missing treatment data (48.7%) were categorized as follow-up/remission cases.
Of 76 patients (median age 50-59 years), 88.2% had squamous cell carcinoma; Stage IIB predominated (47.4%). MRI-CE concordance was 63.2% (κ = 0.58, 95% CI: 0.42-0.74). MRI upstaged 12 cases (15.8%), detecting parametrial (58.3%) or nodal involvement (41.7%), and downgraded 16 (21.1%), often underestimating stromal invasion (37.5%). MRI sensitivity was 63.2%; PPV was 75%. Treatment data, available for 39 patients, showed lower-than-expected CCRT/ICBT use due to resource constraints.
MRI complements CE by enhancing staging accuracy, particularly for occult spread, but does not replace it in resource-limited settings. Standardized MRI protocols and prospective studies are needed to optimize diagnostic and therapeutic outcomes in Nepal.
宫颈癌是尼泊尔面临的一项重大公共卫生挑战,由于筛查和基础设施有限,导致诊断延迟。准确分期对于治疗规划至关重要,根据2018年国际妇产科联盟(FIGO)指南,需将磁共振成像(MRI)与临床检查(CE)相结合。本研究评估了尼泊尔一家三级中心在宫颈癌分期中MRI与CE的一致性,假设二者有中度一致性,即MRI能检测出CE遗漏的隐匿性扩散。
这项回顾性研究(2020 - 2023年)纳入了76例经组织学确诊为宫颈癌且在普尔班查尔癌症医院有完整MRI(1.5T,T2/扩散加权成像/增强扫描)和CE(盆腔检查、穿刺/锥形活检)数据的患者。分期遵循FIGO 2018年指南。单因素分析总结了患者特征;通过MRI敏感性、阳性预测值和科恩κ系数评估一致性。缺失的治疗数据(48.7%)被归类为随访/缓解病例。
76例患者(中位年龄50 - 59岁)中,88.2%为鳞状细胞癌;IIB期为主(47.4%)。MRI与CE的一致性为63.2%(κ = 0.58,95%置信区间:0.42 - 0.74)。MRI使12例(15.8%)患者分期上调,检测出宫旁组织受累(58.3%)或淋巴结受累(41.7%),使16例(21.1%)患者分期下调,常低估间质浸润(37.5%)。MRI敏感性为63.2%;阳性预测值为75%。39例患者有治疗数据,结果显示由于资源限制,同步放化疗/近距离放疗的使用低于预期。
MRI通过提高分期准确性补充了CE,特别是对于隐匿性扩散,但在资源有限的环境中不能替代CE。需要标准化的MRI方案和前瞻性研究来优化尼泊尔的诊断和治疗结果。